- Home
- DGICB vs QURE Comparison
DGICB vs QURE Comparison
Compare DGICB & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICB | QURE |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | Netherlands |
| Employees | 851 | 248 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 565.4M | 663.4M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | DGICB | QURE |
|---|---|---|
| Price | $17.69 | $17.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $44.92 |
| AVG Volume (30 Days) | 2.0K | ★ 3.0M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $2.26 | $126.12 |
| Revenue Next Year | N/A | $210.54 |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.84 | $7.76 |
| 52 Week High | $20.30 | $71.50 |
Technical Indicators
Market Signals| Indicator | DGICB | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 51.28 |
| Support Level | $15.57 | $13.35 |
| Resistance Level | $17.80 | $18.37 |
| Average True Range (ATR) | 0.57 | 1.30 |
| MACD | 0.21 | 0.44 |
| Stochastic Oscillator | 66.75 | 84.25 |
Price Performance
Historical ComparisonAbout DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.